Doravirine is a white tablet embossed with “700” on one side. (Source: aidsinfo.nih)
Doravirine was approved in the US in August 2018 and in Europe in November 2018.
- Doravirine is an NNRTI that is used in combination with other antiretrovirals to treat HIV.
- The standard adult dose is 100 mg.
- Doravirine can be taken with or without food.
- It is approved for people who are using HIV treatment for the first time and who do not have resistance to doravirine.
- The most common side effects are nausea and headache. These were reported in up to 1 in 10 people and were generally mild.
- Potential drug interactions that can reduce doravirine levels include but are not limited to, the following:
- Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin.
- Androgen receptor inhibitor: enzalutamide.
- Antimycobacterials: rifampin, rifapentine.
- St. John’s wort (Hypericum perforatum).
- Doravirine is manufactured by Merck (MSD) with the brand name Pifeltro.
- Doravirine is also available as part of a single-pill fixed dose combination (FDC) with lamivudine and tenfovir DF with the brand name Delstrigo
- For full details please see the full prescribing information.
The European patient information and detailed Product Information for doravirine are available in PDF format from this link at the European Medicines Agency (EMA) website.
The Patient Information is a simplified summary: what the drug is, why it is used, results from studies and cautions including side effects.
The Product Information is a detailed technical summary that you can access as a PDF file by clicking the ‘Product Information’ tab. It describes more precisely how the drug works and how it is processed by your body. This includes, for example, reported food interaction studies in terms of calories or fat content. It includes more details of the study results and a full list of side effects and drug interactions.